Skip to main content

Find Clinical Trials

Home
Conditions
EGFR Activating Mutation

Clinical trial condition

EGFR Activating Mutation

Explore clinical trials studying EGFR Activating Mutation. Study availability and eligibility vary by location and protocol.

20 public trials 8 recruiting studies

Refine in advanced search Browse all conditions

EGFR Activating Mutation trial results

Not Yet Recruiting

Comparative ¹⁸F-FDG and ⁶⁸Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC

NCT07685197

Conditions: EGFR Activating Mutation, EGFR-TKI-resistant Non-Small Cell Lung Cancer, NSCLC, +2 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal Data

NCT07287904

Conditions: Adenocarcinoma, Adenocarcinoma Lung, Adenocarcinoma of Lung, +16 more
Locations: Wuhan Union Hospital Wuhan, Hubei, China

View Trial Details

Not Yet Recruiting

High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC

NCT07182708

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +10 more
Locations: Beijing Cancer Hospital Beijing, Beijing Municipality, China

View Trial Details

Not Yet Recruiting

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

NCT05778149

Conditions: Anlotinib, Aumolertinib, EGFR Activating Mutation, +2 more
Locations: Not specified

View Trial Details

Completed

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

NCT04233021

Conditions: Brain Diseases, Brain Metastases, Brain Neoplasms, +11 more
Locations: Centre Hospitalier Aix-Pertuis Aix-en-Provence, France

CHU Amiens - Groupe Hospitalier Sud Amiens, France

Centre Paul Papin Angers, France

Hôpital privé d'Antony Antony, France

View all 36 locations

View Trial Details

Completed

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NCT05146219

Conditions: Brain Diseases, Brain Metastases, Brain Neoplasms, +11 more
Locations: National Cancer Center/Cancer Hospitial,Chinese Academy of Medical Sciences and Peking Union Medical College Beijing, Beijing Municipality, China

View Trial Details

Completed

SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs

NCT04764214

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: Fudan University Shanghai Cancer Center Shanghai, China

View Trial Details

Completed

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

NCT03544814

Conditions: Adenocarcinoma, Adenocarcinoma of Lung, Carcinoma, +9 more
Locations: Not specified

View Trial Details

Active, Not Recruiting

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

NCT05258279

Conditions: EGFR Activating Mutation, Non-squamous Non-small-cell Lung Cancer
Locations: Juntendo Urayasu Hospital Urayasu, Chiba, Japan

St. Marianna University Hospital Kawasaki, Kanagawa, Japan

Kanagawa Cardiovascular and Respiratory Center Yokohama, Kanagawa, Japan

Kanagawa Cancer Center Yokohama, Kanagawa, Japan

View Trial Details

Active, Not Recruiting

Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC

NCT05244213

Conditions: Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations: Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences Guangzhou, Guangdong, China

View Trial Details